These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27845911)

  • 21. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.
    Jonckheere N; Vasseur R; Van Seuningen I
    Crit Rev Oncol Hematol; 2017 Mar; 111():7-19. PubMed ID: 28259298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.
    Rajurkar M; Dang K; Fernandez-Barrena MG; Liu X; Fernandez-Zapico ME; Lewis BC; Mao J
    Cancer Res; 2017 Jan; 77(2):320-329. PubMed ID: 28069799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?
    Azmi AS; Mohammad RM
    Future Med Chem; 2015; 7(1):5-7. PubMed ID: 25582328
    [No Abstract]   [Full Text] [Related]  

  • 25. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer.
    Rawnaq T; Dietrich L; Wolters-Eisfeld G; Uzunoglu FG; Vashist YK; Bachmann K; Simon R; Izbicki JR; Bockhorn M; Güngör C
    Mol Cancer Res; 2014 May; 12(5):670-80. PubMed ID: 24567526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN.
    Xiong J; Wang D; Wei A; Lu H; Tan C; Li A; Tang J; Wang Y; He S; Liu X; Hu W
    Exp Cell Res; 2017 Dec; 361(2):316-323. PubMed ID: 29111166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early requirement of Rac1 in a mouse model of pancreatic cancer.
    Heid I; Lubeseder-Martellato C; Sipos B; Mazur PK; Lesina M; Schmid RM; Siveke JT
    Gastroenterology; 2011 Aug; 141(2):719-30, 730.e1-7. PubMed ID: 21684285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway.
    Chen Y; Bai X; Zhang Q; Wen L; Su W; Fu Q; Sun X; Lou Y; Yang J; Zhang J; Chen Q; Wang J; Liang T
    Cancer Lett; 2016 Sep; 380(1):98-105. PubMed ID: 27339327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer.
    Yeo D; Phillips P; Baldwin GS; He H; Nikfarjam M
    Int J Cancer; 2017 May; 140(9):2101-2111. PubMed ID: 28109008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rac1 and EGFR cooperate to activate Pak in response to nutrient stress.
    Lee SW; Commisso C
    Biochem Biophys Res Commun; 2020 Dec; 533(3):437-441. PubMed ID: 32972756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis.
    Lee SW; Zhang Y; Jung M; Cruz N; Alas B; Commisso C
    Dev Cell; 2019 Aug; 50(3):381-392.e5. PubMed ID: 31257175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic Cancer: Current Progress and Future Challenges.
    Hussain SP
    Int J Biol Sci; 2016; 12(3):270-2. PubMed ID: 26929733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FAK and paxillin, two potential targets in pancreatic cancer.
    Kanteti R; Batra SK; Lennon FE; Salgia R
    Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.
    Thakur AK; Nigri J; Lac S; Leca J; Bressy C; Berthezene P; Bartholin L; Chan P; Calvo E; Iovanna JL; Vasseur S; Guillaumond F; Tomasini R
    Cell Death Differ; 2016 Aug; 23(8):1358-70. PubMed ID: 26943320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
    Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
    Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-β signalling pathway.
    Zhu Z; Xu Y; Zhao J; Liu Q; Feng W; Fan J; Wang P
    Br J Cancer; 2015 Apr; 112(8):1367-75. PubMed ID: 25867271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAKs in Human Cancer Progression: From Inception to Cancer Therapeutic to Future Oncobiology.
    Kumar R; Li DQ
    Adv Cancer Res; 2016; 130():137-209. PubMed ID: 27037753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.